table stringclasses 2
values | label stringlengths 4 13 | series stringclasses 1
value | value int64 4 44 | unit float64 | source stringclasses 1
value | source_url stringclasses 1
value |
|---|---|---|---|---|---|---|
EMA-authorised biosimilars by year of authorisation | 2019 | Biosimilars | 4 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
EMA-authorised biosimilars by year of authorisation | 2020 | Biosimilars | 8 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
EMA-authorised biosimilars by year of authorisation | 2021 | Biosimilars | 8 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
EMA-authorised biosimilars by year of authorisation | 2022 | Biosimilars | 5 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
EMA-authorised biosimilars by year of authorisation | 2023 | Biosimilars | 7 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
EMA-authorised biosimilars by year of authorisation | 2024 | Biosimilars | 17 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
EMA-authorised biosimilars by year of authorisation | 2025 | Biosimilars | 44 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
EMA-authorised biosimilars by year of authorisation | 2026 | Biosimilars | 14 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Denosumab | Biosimilars | 30 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Aflibercept | Biosimilars | 12 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Ustekinumab | Biosimilars | 11 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Pegfilgrastim | Biosimilars | 11 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Adalimumab | Biosimilars | 10 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Trastuzumab | Biosimilars | 8 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Bevacizumab | Biosimilars | 8 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
The eight molecules with the most authorised biosimilars | Ranibizumab | Biosimilars | 8 | null | EMA, Download medicine data (file of 3 November 2026) | https://www.ema.europa.eu/en/medicines/download-medicine-data |
Biosimilars authorised by the EMA, by year and molecule
crida studio count of the 152 biosimilars for human use authorised in the public EMA file of 3 November 2026. Biosimilars by year of authorisation and by molecule.
The EMA's public medicines file lists 152 authorised biosimilars for human use, based on our download of 3 November 2026. They cover 27 molecules and 41 different holders. 44 of 152 were authorised in 2025, and 26 of those are denosumab. If you sell equipment, consumables or manufacturing services, this is a public list of potential customers and of the molecules where things are moving.
Published by crida studio (Caldes de Malavella, Girona, Spain) on 2026-11-03, last updated on 2026-11-03. Web page with the charts, the analysis and the other languages: https://www.crida.studio/en/insights/guides/ema-approved-biosimilars-2026/
Files
- biosimilars-autoritzats-ema-2026-en.csv
Period covered: 2006/2026.
Geographic coverage: European Union.
Method
We downloaded the file Medicines output, medicines report from the EMA's Download medicine data page. The EMA generated it on 3 November 2026 at 6 am and we downloaded it the same day. We kept the rows with category Human and Biosimilar Yes. That gives 196 rows, and 152 have the status Authorised.
We counted holders without regard to upper or lower case. For the yearly count we used the marketing authorisation date. One authorised medicine, Pavblu, has no such date in the file and is left out of the yearly count, which therefore adds up to 151.
There are limits. The EMA itself says it evaluates the majority of biosimilar applications in the EU, not all of them. We count authorisations, not sales or production volume. One molecule can have several brand names from the same holder.
Sources
- EMA, Download medicine data: https://www.ema.europa.eu/en/medicines/download-medicine-data
- EMA, Medicines output, medicines report file (generated on 3 November 2026): https://www.ema.europa.eu/en/documents/report/medicines-output-medicines-report_en.xlsx
- EMA, Biosimilar medicines. Overview: https://www.ema.europa.eu/en/human-regulatory-overview/biosimilar-medicines-overview
Licence
CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Credit crida studio and link to https://www.crida.studio/en/insights/guides/ema-approved-biosimilars-2026/. The source data keep the terms of each source.
How to cite
crida studio (2026). Biosimilars authorised by the EMA, by year and molecule. https://www.crida.studio/en/insights/guides/ema-approved-biosimilars-2026/
Contact
Also on Harvard Dataverse
The same dataset, with a permanent identifier: https://doi.org/10.7910/DVN/AV52CG
More open data from crida studio: https://github.com/cridastudio/open-data
- Downloads last month
- 47